Allergic Rhinitis Market to Expand Significantly Through 2036 Driven by Rising Disease Burden, Advancements in Biologics, and Emerging Immunotherapy Approaches | DelveInsight

DelveInsight's "Allergic Rhinitis - Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of Allergic Rhinitis, historical and forecasted epidemiology, current treatment practices, emerging therapies, and market trends across the seven major markets (7MM), including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates current treatment algorithms, patient burden, market dynamics, and the commercial potential of emerging therapies expected to reshape the
Allergic Rhinitis market over the forecast period.

Allergic rhinitis is one of the most common chronic allergic disorders worldwide, characterized by sneezing, nasal congestion, rhinorrhea, and nasal itching caused by an IgE-mediated immune response to environmental allergens. Although antihistamines and intranasal corticosteroids remain the mainstay of treatment, growing understanding of type 2 inflammation has accelerated the development of biologics and disease-modifying immunotherapies. DelveInsight anticipates that increasing disease prevalence, greater awareness, improved diagnosis, and the launch of novel therapies will drive sustained market growth through 2036.

Key Takeaways from the Allergic Rhinitis Market Report

• DelveInsight estimates that the Allergic Rhinitis market across the 7MM was valued at nearly USD 10 billion in 2025 and is projected to reach approximately USD 16 billion by 2036, supported by increasing disease prevalence and the launch of innovative therapies.

• The total prevalent cases of Allergic Rhinitis in the 7MM were approximately 180 million in 2025, while diagnosed prevalent cases exceeded 100 million and are expected to continue increasing during the forecast period.

• According to DelveInsight's estimates, the United States accounted for nearly 25 million diagnosed prevalent cases of Allergic Rhinitis in 2025, representing one of the largest patient populations among the seven major markets.

• Among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent patient population in 2025, while Japan also represented a significant disease burden, particularly among patients with tree pollen sensitivity.

• Current treatment options include oral antihistamines, intranasal corticosteroids, leukotriene receptor antagonists (LTRAs), mast cell stabilizers, decongestants, saline irrigation, and allergen immunotherapy, while biologic therapies are expected to reshape future treatment strategies.

• Promising pipeline therapies such as LY3650150 (Lebrikizumab, Eli Lilly) and REGN5713-5714-5715 (Regeneron Pharmaceuticals) are expected to address unmet needs in patients with persistent and moderate-to-severe Allergic Rhinitis.

Read more about the Allergic Rhinitis Market report:
https://www.delveinsight.com/report-store/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Allergic Rhinitis Market

• The Allergic Rhinitis market is expected to experience substantial growth due to the increasing prevalence of allergic diseases worldwide, growing urbanization, environmental pollution, climate-driven prolongation of pollen seasons, and greater patient awareness leading to earlier diagnosis. Increasing healthcare expenditure and continuous improvements in diagnostic technologies are also supporting market expansion.

• Treatment strategies continue to evolve beyond conventional antihistamines and corticosteroids with increasing interest in allergen-specific immunotherapy and targeted biologic therapies. Novel monoclonal antibodies targeting key inflammatory pathways such as IL-13 are expected to offer improved symptom control in patients inadequately managed with existing therapies. Furthermore, advances in sublingual immunotherapy are providing additional long-term disease-modifying treatment options.

• The expanding pipeline, increasing physician awareness, favorable reimbursement initiatives in several countries, and continuous research into allergic inflammation are expected to create significant commercial opportunities over the coming decade. However, treatment adherence, limited efficacy in moderate-to-severe disease, and the high cost of biologics remain important challenges influencing market adoption.

Allergic Rhinitis Market Analysis

According to DelveInsight, the Allergic Rhinitis market across the seven major markets is poised for considerable expansion between 2022 and 2036. Rising disease prevalence, increasing diagnosis rates, and the introduction of novel biologics are expected to transform the competitive landscape. Current therapies primarily provide symptomatic relief, whereas emerging biologics and advanced immunotherapies have the potential to address underlying disease mechanisms and improve long-term clinical outcomes.

The United States currently represents the largest individual market, while Europe and Japan continue to contribute significantly owing to high disease prevalence and established treatment practices. Increasing adoption of allergen immunotherapy, improved patient adherence strategies, and innovative biologic therapies are expected to accelerate market growth throughout the forecast period.

Request a sample and discover the latest advancements in Allergic Rhinitis treatment therapies, emerging drugs, epidemiology, and market forecasts:
https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Allergic Rhinitis Epidemiology Segmentation

The Allergic Rhinitis epidemiology chapter provides comprehensive historical and forecasted patient population data across the seven major markets (7MM), including the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The report analyzes disease burden using multiple epidemiological segments, enabling stakeholders to understand regional trends, patient distribution, and future market opportunities.

DelveInsight estimates that the total prevalent cases of Allergic Rhinitis across the 7MM reached approximately 180 million in 2025, while diagnosed prevalent cases exceeded 100 million. The patient population is expected to increase steadily through 2036, driven by growing urbanization, increasing environmental pollution, climate-driven extension of pollen seasons, and greater disease awareness.
Within the United States, diagnosed prevalence was estimated at nearly 25 million cases in 2025. Moderate disease represented the largest proportion of diagnosed patients, accounting for approximately 55%, followed by mild (25%) and severe (20%) disease. The report also evaluates patients according to age groups, disease severity, allergen sensitivity, disease duration, and disease type, providing a detailed assessment of evolving epidemiological trends.

Among the European countries, Germany accounted for the largest diagnosed patient population in 2025. Japan also represents a significant disease burden, particularly among patients with tree pollen allergy, reflecting the regional impact of seasonal allergens. These epidemiological insights are expected to guide future treatment strategies and commercial planning across the major pharmaceutical markets.

The report segments the Allergic Rhinitis patient population into:

• Total Prevalent Cases of Allergic Rhinitis
• Total Diagnosed Prevalent Cases of Allergic Rhinitis
• Age-specific Diagnosed Prevalent Cases
• Severity-specific Diagnosed Prevalent Cases
• Allergen-specific Diagnosed Prevalent Cases
• Type-specific Diagnosed Prevalent Cases (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, and Mixed)

• Duration-specific Diagnosed Prevalent Cases (Intermittent and Persistent)
Read more about the Allergic Rhinitis Market report:
https://www.delveinsight.com/report-store/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr
Allergic Rhinitis Treatment Market

• The management of Allergic Rhinitis focuses on relieving symptoms, improving quality of life, and minimizing exposure to allergens. Current treatment strategies include allergen avoidance, intranasal corticosteroids, second-generation oral antihistamines, leukotriene receptor antagonists, mast cell stabilizers, nasal decongestants, saline nasal irrigation, and allergen immunotherapy. Intranasal corticosteroids remain the most effective first-line anti-inflammatory treatment, while allergen immunotherapy is currently the only disease-modifying therapeutic approach capable of providing long-term clinical benefits.

• The Allergic Rhinitis therapeutic landscape continues to evolve with increasing interest in targeted biologics for patients with persistent or inadequately controlled disease. Emerging therapies are designed to address the underlying type 2 inflammatory pathways responsible for allergic responses, offering the potential for improved efficacy compared with conventional symptomatic treatments.

• According to DelveInsight, the Allergic Rhinitis market is anticipated to witness significant growth during the forecast period owing to rising disease prevalence, greater diagnosis rates, increasing adoption of immunotherapy, favorable reimbursement policies, and the expected launch of novel biologic therapies. However, challenges such as poor long-term treatment adherence, high biologic costs, and suboptimal symptom control with existing therapies continue to represent important unmet needs within the market.
Download the Allergic Rhinitis Market report sample here:
https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Allergic Rhinitis Emerging Drugs

The Allergic Rhinitis pipeline remains relatively focused, with several innovative therapies under clinical development aimed at improving outcomes for patients with moderate-to-severe disease and those who remain symptomatic despite standard therapy.
Some of the key emerging therapies include:
• LY3650150 (Lebrikizumab) - Eli Lilly
• REGN5713-5714-5715 - Regeneron Pharmaceuticals
• MAM-1004-1/Budesolv - Marinomed Biotech AG

Among these, LY3650150 (Lebrikizumab) is a monoclonal antibody targeting interleukin-13 (IL-13), a cytokine central to type 2 inflammation. The therapy is currently being investigated in Phase III clinical development for perennial allergic rhinitis and has the potential to become one of the first biologic therapies specifically developed for this patient population.

REGN5713-5714-5715 is an investigational combination of monoclonal antibodies developed by Regeneron Pharmaceuticals targeting Bet v 1, the primary birch pollen allergen. The therapy has completed Phase III clinical evaluation for birch pollen-induced seasonal allergic rhinitis and represents an innovative allergen-specific biologic approach for patients with seasonal disease.
In addition, Marinomed Biotech AG is advancing MAM-1004-1/Budesolv, a drug-device combination utilizing proprietary Marinosolv technology. The therapy has successfully completed Phase III clinical studies and is currently progressing toward regulatory submission, further expanding future treatment possibilities for severe Allergic Rhinitis.

Table of Contents

1. Key Insights
2. Report Introduction
3. Allergic Rhinitis Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Disease Background and Overview
7. Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Drugs
12. Allergic Rhinitis Market Analysis
13. KOL Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Request a sample and discover the latest advancements in Allergic Rhinitis treatment therapies, epidemiology, and market forecasts:
https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Contact Person:
Kirti Sharma
Email:
info@delveinsight.com
Phone:
+1-469-945-7679
Website:
https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.